SynthesisFrontiers in medicine2026
Efficacy and safety of plant-derived bioactive compounds in the treatment of psoriasis vulgaris: a systematic review and network meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Long-term use of conventional therapy (CT) for psoriasis vulgaris (PV) is often constrained by adverse effects and costs. While oral plant-derived bioactive compounds show clinical promise as adjunctive treatments, the relative efficacy and safety of these compounds and their combination regimens remain poorly defined due to a lack of head-to-head comparisons. This systematic review and network meta-analysis aimed to compare and rank the efficacy and safety of different oral plant-derived bioactive compounds and their combination regimens for PV. Methods: Randomized controlled trials investigating the effects of plant-derived bioactive compounds, such as compound glycyrrhizin (CG), tripterygium glycosides (TG), and total glucosides of paeony (TGP), on PV were retrieved from Chinese and English databases via computer searches. The main outcome measures included the Psoriasis Area and Severity Index (PASI), CD4 Results: We included 84 randomized controlled trials comprising 7,544 patients across 15 treatment regimens. Most combination therapies significantly outperformed monotherapy in PASI reduction. TG combined with topical therapy (TOP) produced the greatest reduction in PASI scores [mean difference (MD) = -13.96, 95% confidence interval (CI) (-16.88, -11.03)], with the highest surface under the cumulative ranking curve (SUCRA) value of 99.80%. Individual compounds showed distinct advantages for specific therapeutic targets. CG + TOP proved most effective for reducing IL-23 levels (SUCRA = 97.30%), while CG + NB-UVB achieved the greatest IL-17 reduction (SUCRA = 91.20%). CG + CT best restored CD4 Conclusion: Combining plant-derived compounds with CT may enhance short-term, outcome-specific efficacy. TG + TOP showed the greatest PASI reduction. Immunologically, CG-based regimens optimized IL-23/IL-17 suppression and CD4 Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261304681, identifier (CRD420261304681).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.